References
- Lanier, L.L., Testi, R., Bindl. J. and Phillips, J.H. (1989) "Identity of Leu-I 9 ((1)56) leukocyte differentiation antigen and neural cell adhesion molecule", J. Ery. Med. 169(6), 2233–2238.
- Walsh, F.S. and Doherty, P. (1997) "Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance", Anna. Rev. Cell. Den. Biol. 13, 425–456.
- Cunningham. B.A., Hemperly, IL, Murray, B.A., Prediger, L.A., Brackenbury, R. and Edelman, G.M. (1987) "Neural cell adhesion molecule: structure, immunoglobufin-like domains, cell surface modulation, and alternative RNA splicing", Science 236(4803), 799–806.
- Lanier, L.L., Le. A.M., Civin, C.I,, Loken, M.R. and Phillips, J.H. (1986) "The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes", J. Immunol. 136(12), 4480–4486.
- Chang, C.C., Eshoa, C., Kampalath, B., Shidham, V.R. and Perkins, S. (2000) "Immunophenotypic profile of myeloid cells in granulocytic sarcoma by immunohistochemistry. Correlation with blast differentiation in bone marrow", Am. Clin. Pathol. 114(5), 807–811.
- Garin-Chesa, P., Fellinger, El., Huvos, A.G., Beresford, H.R., Melamed, M.R., Triche, T.J., etal. (1991) "Immunohistochemical analysis of neural cell adhesion molecules. Differential expression in small round cell tumors of childhood and adolescence", Am. .1. Pathol. 139(2). 275–286.
- Zeromski, J., Lawniczak, M., Galbas, K., Jenek, R. and Golusinski, P. (1998) "Expression of CD56/N-CAM antigen and some other adhesion molecules in various human endocrine glands", Folio Histochem. Cytobia 36(3), 119–125.
- Mechtersheimer, G., Staudter, M. and Moller, P. (1991) "Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors", Cancer Res. 51(4), 1300–1307.
- Mraz-Gernhard, S., Natkunam, Y, Hoppe, R.T., LeBoit, P., Kohler, S. and Kim, Y.H. (2001) "Natural killer/natural killer-like 1-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course", J. Clin. Oncol. 19(8), 2179–2188.
- Jaffe, E.S., Harris, N.L., Vardiman, LW., eds. (2001) "World Health Organization Classification of Tumours", Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. (IARC Press, Lyon).
- Murray, C.K., Estey, E., Paietta, E., Howard, R.S., Edenfield, W.J., Pierce, S., Cr al. (1999) "CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?", J. UM °mot 17(1), 293–297.
- Baer, M.R., Stewart, C.C., Lawrence, D., Arthur, D.C., Byrd, J.C.. Davey, ER., et al. (1997) "Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;2I)(q22;q22)", Blood 90(4), 1643–1648.
- Shikarni, M., Miwa, H.. Nishii, K., Takahashi, T., Shiku, H., Tsutani, It, et al. (1999) "Myeloid differentiation antigen and cytokine receptor expression on acute myelocytic leukaemia cells with t(16:21)(p11:q22): frequent expression of CD56 and interleukin-2 receptor alpha chain", Br .1. Haematol. 105(3), '711–719.
- Daniels, J.T., Davis, B.J., Houde-McGrail, L. and Byrd, J.C. (1999) "Clonal selection of CD56+ t(8:21) AML blasts: further suggestion of the adverse clinical significance of this biological marker?", Br J. Haentatot 107(2), 381–383.
- Ferrara, F., Morabito, F., Martino, B., Specchia, G., Liso, V., Mobile, F., et al. (2000) "CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy", J. Glitz. Oncol. 18(6), 1295–1300.
- Paietta, E., Neuberg, D., Richards, S., Bennett, J.M., Han, L., Racevskis. I., etal. (2001) "Rare adult acute lymphocytic leukemia [3] 151 with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity". Am. J. Hematol. 66(3), 189–196.
- Manaloor, E.J., Neiman, R.S., Heilman, D.K. Albitar, M., Casey, T.. Vattuone, T., et al. (2000) "Irnmunohistochemistry can be used to subtype acute myeloid leukemia in routinely processed bone marrow biopsy specimens. Comparison with flow cytometry", Am. J. Clin. Pathol. 113(6), 814–822.
- Sillaber, C., Walchshofer, S., Mosberger, I., Gaiger, A., Simonitsch, I., Chott, A., et al. (1999) "Immunophenotypic characterization of human bone marrow endosteal cells", Tissue Antigens 53(6). 559–568.
- Mann, KR, DeCastro, CM., Liu, I.. Moore, J.0., Bigner. S.H. and Traweek, S.T. (1997) "Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes", Am. J. Gin. Pathol, 107(6), 653–660.
- Scott, A.A., Head, DR., Kopecicy, K.J., Appelbaum, FR., Theil, K.S. and Greyer. M.R. etal. (1994) "1-ILA-DR-, CD33+. CD56+, CD16 - myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3", Blood 84(1), 244–255.
- Neame, P.B., Soamboonsnip, P., Leber, B., Carter, RE, Sunisloe, L., Patterson, W., etal. (1997) -Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants", Am. J. Hematol. 56(3), 131–142,